Percutaneous transluminal renal artery stenting (PTRAS) continues to be proved to haven’t any even more benefit than medication only in treating atherosclerotic renal artery stenosis (ARAS). a two-year follow-up. The still left ventricular mass index (LVMI) and various other clinical characteristics had been compared between groupings. Through the follow-up period, a considerable reduction in systolic… Continue reading Percutaneous transluminal renal artery stenting (PTRAS) continues to be proved to